What Happens When the Hemostatic Plan Is Missed

What Happens When the Hemostatic Plan Is Missed

Postoperative bleeding, rescue therapy, and prevention in type 2B von Willebrand disease

By William C. Aird, MD

Case Presentation

A 27-year-old man with type 2B von Willebrand disease (VWD) undergoes urgent incision and drainage of a perirectal abscess.

He has a lifelong history of bleeding beginning shortly after circumcision. During childhood he experienced recurrent epistaxis and gum bleeding, occasionally requiring treatment with Humate-P. He routinely received VWF-containing concentrate before invasive procedures and had never experienced significant postoperative bleeding.

His medical history is otherwise notable for well-controlled HIV infection.

Because the anorectal abscess requires urgent drainage, surgery proceeds without preoperative VWF replacement.

Preoperative laboratory studies show:

The procedure itself is uncomplicated.

Within hours, however, persistent bleeding develops from the surgical wound.

Which factor most likely explains this patient’s postoperative bleeding?

Explanation

Patients with type 2B VWD require anticipatory hemostatic planning before procedures.

Although this patient had previously undergone procedures successfully, those procedures had been covered with VWF-containing concentrate.

The major difference in this case was the absence of planned perioperative hemostatic support.

Rescue Therapy

Over the next 24 hours, persistent wound oozing continues.

His hemoglobin falls dramatically:

Red blood cell transfusion is required.

Initially he receives desmopressin followed shortly thereafter by Humate-P.

Bleeding improves rapidly after VWF replacement.

Which treatment most directly corrected the underlying hemostatic defect?

Explanation

Humate-P provides functional VWF capable of restoring platelet adhesion and stabilizing factor VIII.

It directly replaces the defective protein responsible for bleeding.

Red blood cell transfusion treats blood loss rather than the hemostatic defect itself.

Why is desmopressin generally avoided in type 2B VWD?

Explanation

Desmopressin releases endogenous VWF from endothelial storage sites.

In type 2B VWD, that VWF retains increased affinity for platelet GPIb.

The result may be:

• enhanced platelet aggregation,
• transient thrombocytopenia,
• less effective hemostasis than VWF replacement.

Current practice generally favors VWF-containing concentrate for major bleeding in type 2B VWD.

Although true thrombocytopenia was not clearly documented in this case, the finding reinforced concern regarding desmopressin in type 2B disease.

Learning From the Event

The patient’s subsequent procedures are managed very differently.

Fistulotomy

He receives:

• Humate-P before surgery
• additional postoperative doses

No excessive bleeding occurs.

Wisdom Tooth Extraction

He receives:

• Humate-P before extraction
• additional daily doses for two days
• oral aminocaproic acid beginning before surgery and continuing for five days afterward

Again, there are no bleeding complications.

Rather than reacting to bleeding after it occurred, the clinical team translated knowledge of the patient’s bleeding disorder into a proactive procedural plan.

What best explains the different outcomes between the first and subsequent procedures?

Explanation

The most important difference was not the procedure itself but the planning.

For later procedures, the team anticipated bleeding risk and implemented:

• VWF replacement,
• adjunctive antifibrinolytic therapy,
• postoperative monitoring.

The result was successful hemostasis despite invasive procedures.

Procedural Planning

Successful management of invasive procedures in VWD begins long before the first incision.

Important elements include:

• confirming the VWD subtype,
• assessing the patient’s previous responses to therapy,
• selecting the appropriate VWF-containing concentrate,
• planning adjunctive antifibrinolytic therapy,
• coordinating infusion timing with the procedural team,
• arranging postoperative monitoring and follow-up.

This patient’s first procedure illustrates the consequences of omitting that planning.

His later procedures demonstrate how thoughtful preparation can largely prevent bleeding complications.

Teaching Points

• Patients with type 2B VWD require procedure-specific hemostatic planning before invasive procedures.
• VWF-containing concentrate is the preferred treatment for major bleeding in type 2B VWD.
• Desmopressin is generally avoided because it may increase abnormal platelet–VWF interactions and precipitate thrombocytopenia.
• Antifibrinolytic therapy provides important adjunctive protection during mucosal procedures such as dental extraction.
• A patient’s previous response to replacement therapy should inform future procedural planning.
• Successful perioperative management depends as much on preparation as on treatment.

Why This Case Matters

Major bleeding in inherited bleeding disorders is often viewed as an unavoidable consequence of abnormal hemostasis. This case illustrates the opposite principle.

The patient’s first operation was complicated by severe postoperative hemorrhage not because his disorder had changed, but because his hemostatic plan was absent. Once his diagnosis was translated into a structured perioperative strategy—including timely VWF replacement, adjunctive antifibrinolytic therapy, and coordinated postoperative management—subsequent invasive procedures were completed without significant bleeding.

The lesson extends beyond type 2B VWD. Knowledge of a bleeding disorder has little value unless it changes what happens before the procedure begins. In procedural hemostasis, success is often determined not by the rescue therapy that follows bleeding, but by the plan that prevents bleeding from occurring in the first place.